VIA
Vident Investment Advisory Portfolio holdings
AUM
$2.9B
This Quarter Return
+1.41%
1 Year Return
+24.65%
3 Year Return
+82.72%
5 Year Return
+113.39%
10 Year Return
–
AUM
$712M
AUM Growth
+$712M
(+43,807%)
Cap. Flow
-$653M
Cap. Flow
% of AUM
-91.83%
Top 10 Holdings %
Top 10 Hldgs %
6.85%
Holding
408
New
37
Increased
7
Reduced
332
Closed
32
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$9.68M |
| 2 |
Vanguard FTSE Emerging Markets ETF
VWO
|
$2.06M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
$1.87M |
| 4 |
YHOO
Yahoo Inc
YHOO
|
$1.31M |
| 5 |
Signet Jewelers
SIG
|
$1.09M |
Top Sells
| 1 |
Amazon
AMZN
|
$15.2M |
| 2 |
Microsoft
MSFT
|
$7.69M |
| 3 |
Apple
AAPL
|
$6.46M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
$5.45M |
| 5 |
Gilead Sciences
GILD
|
$5.09M |
Sector Composition
| 1 | Technology | 14.09% |
| 2 | Financials | 13.4% |
| 3 | Healthcare | 12.23% |
| 4 | Consumer Discretionary | 11% |
| 5 | Industrials | 9.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
MacroGenics
MGNX
$112M
| $742K | 0.1% | 27,483 -18,259 | -40% | -$493K |
|
302
Visa
V
$683B
| $741K | 0.1% | 8,136 -48,292 | -86% | -$4.4M |
|
303
Atara Biotherapeutics
ATRA
$84.6M
| $740K | 0.1% | 32,879 -9,303 | -22% | -$209K |
|
304
HCA Healthcare
HCA
$94.5B
| $739K | 0.1% | +9,594 | New | +$739K |
|
305
TransDigm Group
TDG
$78.8B
| $739K | 0.1% | 2,264 -6,426 | -74% | -$2.1M |
|
306
Universal Health Services
UHS
$11.6B
| $734K | 0.1% | +5,477 | New | +$734K |
|
307
Procter & Gamble
PG
$368B
| $732K | 0.1% | 8,650 -17,886 | -67% | -$1.51M |
|
308
Labcorp
LH
$23.1B
| $731K | 0.1% | +5,615 | New | +$731K |
|
309
Bristol-Myers Squibb
BMY
$96B
| $730K | 0.1% | 9,926 -44,306 | -82% | -$3.26M |
|
310
Novartis
NVS
$245B
| $730K | 0.1% | 8,853 -10,007 | -53% | -$825K |
|
311
Sherwin-Williams
SHW
$91.2B
| $725K | 0.1% | +1,996 | New | +$725K |
|
|
BLUE
312
DELISTED
bluebird bio
BLUE
| $722K | 0.1% | 16,673 -6,273 | -27% | -$272K |
|
313
Ross Stores
ROST
$48.1B
| $718K | 0.1% | 12,664 -23,246 | -65% | -$1.32M |
|
|
LUMO
314
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $710K | 0.1% | 63,042 +23,554 | +60% | +$265K |
|
|
ABMD
315
DELISTED
Abiomed Inc
ABMD
| $708K | 0.1% | 6,476 -18,464 | -74% | -$2.02M |
|
316
Humana
HUM
$36.5B
| $703K | 0.1% | 3,910 -7,272 | -65% | -$1.31M |
|
|
BLCM
317
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $701K | 0.1% | 54,072 -21,670 | -29% | -$281K |
|
318
Medtronic
MDT
$119B
| $697K | 0.1% | 8,033 -19,769 | -71% | -$1.72M |
|
319
Iovance Biotherapeutics
IOVA
$807M
| $694K | 0.1% | 85,707 -91,013 | -52% | -$737K |
|
320
PNC Financial Services
PNC
$81.7B
| $694K | 0.1% | 8,529 -9,037 | -51% | -$735K |
|
321
CytomX Therapeutics
CTMX
$336M
| $692K | 0.1% | 67,721 -6,109 | -8% | -$62.4K |
|
322
Johnson Controls International
JCI
$69.9B
| $687K | 0.1% | +15,523 | New | +$687K |
|
|
FPRX
323
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $687K | 0.1% | 16,615 -18,681 | -53% | -$772K |
|
324
Eli Lilly
LLY
$657B
| $685K | 0.1% | 8,704 -19,656 | -69% | -$1.55M |
|
|
WEB
325
DELISTED
Web.com Group, Inc.
WEB
| $685K | 0.1% | +37,704 | New | +$685K |
|